GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib missed its primary 6-minute walk distance endpoint in pulmonary arterial hypertension. In May 2025, CEO Faheem Hasnain told investors the Company was "more optimistic than ever about the likelihood of achieving positive results." If you lost money on GOSS shares, submit your information now to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. During the Q1 2025 earnings call on May 15, 2025, CEO Hasnain stated: "The baseline characteristics of the patients enrolled thus far are precisely what we have targeted." He further claimed the Company had "over 90% power given the sample size" and that the enrolled patient population indicated "a materially more severe population than the TORREY study." He told i
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.MarketBeat
- GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLPPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSGlobeNewswire
- GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSPR Newswire
GOSS
Earnings
- 11/5/25 - Miss
GOSS
Sec Filings
- 3/2/26 - Form SCHEDULE
- 2/24/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- GOSS's page on the SEC website